Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 12, 2019
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Entity Registrant Name	ATRECA, INC.
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001532346
Amendment Flag	false
Entity Ex Transition Period	false
Class A common stock
Entity Common Stock, Shares Outstanding		22,026,588
Class B common stock
Entity Common Stock, Shares Outstanding		5,934,191

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 166,144	$ 114,504
Investments	34,894
Prepaid expenses and other current assets	5,434	2,721
Total current assets	206,472	117,225
Property and equipment, net	4,740	4,143
Deposits and other	1,506	316
Total assets	212,718	121,684
Current Liabilities
Accounts payable	2,757	1,307
Accrued expenses	4,519	3,008
Other current liabilities	264	247
Total current liabilities	7,540	4,562
Capital lease obligations, net of current portion	65	100
Deferred rent	118	6
Preferred stock warrant liability		380
Total liabilities	7,723	5,048
Stockholders’ equity (deficit)
Additional paid-in capital	348,942	3,593
Accumulated other comprehensive income (loss)	43	(4)
Accumulated deficit	(143,993)	(96,622)
Total stockholders’ equity (deficit)	204,995	(93,033)
Total liabilities and stockholders’ equity	212,718	121,684
Series A convertible preferred stock
Current Liabilities
Convertible preferred stock		55,030
Series B convertible preferred stock
Current Liabilities
Convertible preferred stock		34,333
Series C1 convertible preferred stock
Current Liabilities
Convertible preferred stock		65,691
Series C2 convertible preferred stock
Current Liabilities
Convertible preferred stock		$ 54,615
Class A common stock
Stockholders’ equity (deficit)
Common stock	2
Class B common stock
Stockholders’ equity (deficit)
Common stock	$ 1

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Series A convertible preferred stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	100,000,000	32,133,287
Convertible preferred stock, shares issued	0	5,305,513
Convertible preferred stock, shares outstanding	0	5,305,513
Convertible preferred stock, aggregate liquidation preference	$ 58,892	$ 58,892
Series B convertible preferred stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	100,000,000	18,008,749
Convertible preferred stock, shares issued	0	3,001,421
Convertible preferred stock, shares outstanding	0	3,001,421
Convertible preferred stock, aggregate liquidation preference	$ 35,000	$ 35,000
Series C1 convertible preferred stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	50,000,000	54,184,549
Convertible preferred stock, shares issued	0	5,007,134
Convertible preferred stock, shares outstanding	0	5,007,134
Convertible preferred stock, aggregate liquidation preference	$ 70,000	$ 70,000
Series C2 convertible preferred stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	50,000,000	23,605,150
Convertible preferred stock, shares issued	0	3,934,191
Convertible preferred stock, shares outstanding	0	3,934,191
Convertible preferred stock, aggregate liquidation preference	$ 55,000	$ 55,000
Class A common stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	650,000,000	191,398,492
Common stock, shares issued	22,025,852	2,119,872
Common stock, shares outstanding	22,025,852	2,119,872
Class B common stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	23,605,150
Common stock, shares issued	5,934,191	0
Common stock, shares outstanding	5,934,191	0

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Expenses
Research and development	$ 12,812	$ 7,820	$ 40,447	$ 21,882
General and administrative	4,864	1,875	10,919	4,807
Total expenses	17,676	9,695	51,366	26,689
Interest and other income (expense)
Other income	619	100	1,805	660
Interest income	1,189	23	2,328	112
Interest expense	(1)	(3)	(5)	(7)
Preferred stock warrant liability revaluation		(57)	(123)	(30)
Foreign exchange loss	(1)		(1)
Loss on disposal of property and equipment			(7)	(1)
Loss before income tax expense	(15,870)	(9,632)	(47,369)	(25,955)
Income tax expense	(1)		(2)	(1)
Net loss	$ (15,871)	$ (9,632)	$ (47,371)	$ (25,956)
Net loss per share, basic and diluted	$ (0.57)	$ (4.56)	$ (4.03)	$ (12.35)
Weighted-average shares used in computing net loss per share, basic and diluted	27,949,682	2,112,180	11,747,825	2,101,030

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (15,871)	$ (9,632)	$ (47,371)	$ (25,956)
Other comprehensive income (loss);
Unrealized gain (loss) on fair value of investments	(41)	6	48	27
Unrealized gain (loss) on currency translation	(2)	10	(1)	(14)
Comprehensive loss	$ (15,914)	$ (9,616)	$ (47,324)	$ (25,943)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Convertible preferred stock (as converted)	Total
Balances at beginning at Dec. 31, 2017					$ 89,362
Balances at beginning (in shares) at Dec. 31, 2017					8,306,934
Balances at beginning at Dec. 31, 2017		$ 2,130	$ (14)	$ (58,682)		$ (56,566)
Balances at beginning (in shares) at Dec. 31, 2017	2,092,040
Issuance of convertible preferred stock					$ 120,313
Issuance of convertible preferred stock (in shares)					8,941,325
Issuance of common stock upon initial public offering, net (in shares)	22,923
Issuance of common stock upon exercise of options		30				30
Stock-based compensation		833				833
Unrealized gain (loss) on fair value of investments			27			27
Unrealized gain (loss) on currency translation			(14)			(14)
Net loss				(25,956)		(25,956)
Balances at end at Sep. 30, 2018					$ 209,675
Balances at end (in shares) at Sep. 30, 2018					17,248,259
Balances at end at Sep. 30, 2018		2,993	(1)	(84,638)		(81,646)
Balances at end (in shares) at Sep. 30, 2018	2,114,963
Balances at beginning at Jun. 30, 2018					$ 89,362
Balances at beginning (in shares) at Jun. 30, 2018					8,306,934
Balances at beginning at Jun. 30, 2018		2,629	(17)	(75,006)		(72,394)
Balances at beginning (in shares) at Jun. 30, 2018	2,110,540
Issuance of convertible preferred stock					$ 120,313
Issuance of convertible preferred stock (in shares)					8,941,325
Issuance of common stock upon exercise of options		21				21
Issuance of common stock upon exercise of options (in shares)	4,423
Stock-based compensation		343				343
Unrealized gain (loss) on fair value of investments			6			6
Unrealized gain (loss) on currency translation			10			10
Net loss				(9,632)		(9,632)
Balances at end at Sep. 30, 2018					$ 209,675
Balances at end (in shares) at Sep. 30, 2018					17,248,259
Balances at end at Sep. 30, 2018		2,993	(1)	(84,638)		(81,646)
Balances at end (in shares) at Sep. 30, 2018	2,114,963
Balances at beginning at Dec. 31, 2018					$ 209,668
Balances at beginning (in shares) at Dec. 31, 2018					17,248,259
Balances at beginning at Dec. 31, 2018		3,593	(4)	(96,622)		(93,033)
Balances at beginning (in shares) at Dec. 31, 2018	2,119,872
Conversion of convertible preferred stock					$ (209,668)	209,669
Conversion of convertible preferred stock (in shares)					(17,248,259)
Conversion of convertible preferred stock	$ 2	209,666				209,668
Conversion of convertible preferred stock (in shares)	17,248,259
Issuance of common stock upon initial public offering, net	$ 1	130,785				130,786
Issuance of common stock upon initial public offering, net (in shares)	8,452,500
Exercise of warrants (in shares)	62,936
Issuance of common stock upon exercise of options		241				241
Issuance of common stock upon exercise of options (in shares)	67,244
Vesting of early exercised stock options		8				8
Issuance of common stock under the Employee Stock Purchase Plan		133				133
Issuance of common stock under the Employee Stock Purchase Plan (shares)	9,232
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital		503				503
Stock-based compensation		4,013				4,013
Unrealized gain (loss) on fair value of investments			48			48
Unrealized gain (loss) on currency translation			(1)			(1)
Net loss				(47,371)		(47,371)
Balances at end at Sep. 30, 2019	$ 3	348,942	43	(143,993)		204,995
Balances at end (in shares) at Sep. 30, 2019	27,960,043
Balances at beginning at Jun. 30, 2019	$ 3	346,915	86	(128,122)		218,882
Balances at beginning (in shares) at Jun. 30, 2019	27,947,201
Issuance of common stock upon exercise of options		10				10
Issuance of common stock upon exercise of options (in shares)	3,610
Vesting of early exercised stock options		6				6
Issuance of common stock under the Employee Stock Purchase Plan		133				133
Issuance of common stock under the Employee Stock Purchase Plan (shares)	9,232
Stock-based compensation		1,878				1,878
Unrealized gain (loss) on fair value of investments			(41)			(41)
Unrealized gain (loss) on currency translation			(2)			(2)
Net loss				(15,871)		(15,871)
Balances at end at Sep. 30, 2019	$ 3	$ 348,942	$ 43	$ (143,993)		$ 204,995
Balances at end (in shares) at Sep. 30, 2019	27,960,043

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Flows from Operating Activities
Net loss	$ (47,371)	$ (25,956)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,218	1,027
Loss on disposal of property and equipment	7	1
Stock-based compensation	4,013	832
Preferred stock warrant liability revaluation	123	30
Accretion of discount on investments	(686)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,714)	(61)
Accounts payable	1,450	508
Accrued expenses	1,511	(328)
Other current liabilities	(11)	205
Deferred rent	141	16
Net cash used in operating activities	(42,319)	(23,726)
Cash Flows from Investing Activities
Purchase of property and equipment	(1,822)	(1,326)
Purchase of investments	(84,160)
Proceeds from maturities of investments	50,000	22,397
Change in deposits	92	(3)
Net cash provided by (used in) investing activities	(35,890)	21,068
Cash Flows from Financing Activities
Proceeds from issuance of convertible preferred stock, net		120,312
Proceeds from the issuance of common stock under the Employee Stock Purchase Plan	133
Proceeds from exercise of stock options	249	30
Proceeds from initial public offering, net	133,633
Principal payments on capital lease obligations	(36)	(40)
Payments of initial offering costs	(2,848)
Net cash provided by financing activities	131,131	120,302
Net change in cash, cash equivalents and restricted cash	52,922	117,644
Cash, cash equivalents and restricted cash, beginning of period	114,504	8,242
Cash, cash equivalents and restricted cash, end of period	167,426	125,886
Supplemental Disclosure of Cash Flow Information
Cash paid for interest	5	7
Cash paid for income taxes	1	$ 1
Supplemental Schedule of Non-Cash Investing and Financing Activities
Conversion of redeemable convertible preferred stock to common stock	209,669
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital	503
Vesting of early exercised common stock options	$ 8

Business	9 Months Ended
Business	Sep. 30, 2019
Business
Business	1. Business Nature of Business Atreca, Inc. (the “Company”) was incorporated in the State of Delaware on June 11, 2010 (“inception date”), and is located in Redwood City, California. In April 2016, the Company formed a wholly owned subsidiary, Atreca Pte. Ltd., in Singapore. The Company is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The Company's lead product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The Company operates in a single segment. Since inception, the Company has been primarily engaged in research and development, raising capital, building its management team and building its intellectual property portfolio. Reverse Stock Split On June 7, 2019, the Company effected a 1-for-6 reverse stock split of all classes of its capital stock. Upon the effectiveness of the reverse stock split, (i) every one share of the Company’s outstanding capital stock was combined into one-sixth of one share of the same class and series of capital stock, (ii) the number of shares of its Class A common stock and its Series A preferred stock for which each outstanding option or warrant, to purchase its Class A common stock and its Series A preferred stock is exercisable was proportionally decreased on a 1-for-6 basis and (iii) the exercise price of each outstanding option or warrant to purchase its Class A common stock and its Series A preferred stock was proportionately increased on a 1-for-6 basis. The par value per share of its common stock and preferred stock were not adjusted as a result of the reverse stock split. Initial Public Offering In June 2019, the Company closed its initial public offering (“IPO”) of 6,452,500 shares of its Class A common stock and 2,000,000 shares of its Class B common stock at an offering price of $17.00 per share, including 1,102,500 shares pursuant to the underwriters’ option to purchase additional shares of the Company’s Class A common stock. The Company received net proceeds of $130.8 million, after deducting underwriting discounts and commissions of $10.1 million and offering expenses of $2.8 million. Immediately prior to the closing of the IPO, all outstanding shares of the Company’s convertible Series A preferred stock, convertible Series B preferred stock and convertible Series C1 preferred stock automatically converted into 13,314,068 shares of the Company’s Class A common stock and all outstanding shares of the Company’s convertible Series C2 preferred stock automatically converted into 3,934,191 shares of the Company’s Class B common stock. Immediately prior to the closing of the IPO, the Company issued 62,936 shares of Class A common stock upon the exercise of an outstanding warrant. The Company reclassified $209.7 million from temporary equity to Class A common stock, Class B common stock, and additional paid-in-capital on its consolidated balance sheet. Deferred Offering Cost Deferred offering cost of $2.8 million, consisting of legal, accounting and other fees and costs related to the IPO, were reclassified to additional paid-in capital as a reduction of the proceeds upon the closing of the IPO in June 2019. During the nine months ended September 30, 2019, $2.8 million of the deferred offering costs were paid.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2019

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and accounts have been eliminated. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company’s final prospectus for its IPO dated as of June 19, 2019 and filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on June 20, 2019.

Prior period reclassification

An immaterial reclassification of prior period amounts has been made to conform to the current period presentation.

Principles of Consolidation

The condensed consolidated financial statements include accounts of the Company and its wholly owned subsidiary. All significant intercompany accounts and transactions are eliminated upon consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of income and expenses in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates in the consolidated financial statements include estimated useful lives of property and equipment, impairment of long-lived assets, accrued expenses, valuation of deferred income tax assets, fair value of warrants issued to purchasers of shares of preferred stock and common stock and fair value of options granted under the Company's stock option plan.

Unaudited Interim Condensed Consolidated Financial Statements

The accompanying condensed consolidated financial statements are unaudited. The unaudited interim condensed financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the Company’s financial position as of September 30, 2019 and its results of operations and cash flows for the nine months ended September 30, 2019 and 2018. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three-month and nine-month periods are also unaudited. The condensed results of operations for the three months ended and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2018 included herein was derived from the audited consolidated financial statements as of that date.

Other Income

Other income is comprised of amounts earned from services performed under service agreements. Beginning January 1, 2018, the Company follows the provisions of Accounting Standards Update 2014-09 Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“Topic 606”). The guidance provides a unified model to determine how income is recognized.

In determining the appropriate amount of other income to be recognized as it fulfills its obligations under the agreements, the Company performs the following steps: (i) identifies the promised goods or services in the contract; (ii) determines whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measures the transaction price, including the constraint on variable consideration; (iv) allocates the transaction price to the performance obligations based on estimated selling prices; and (v) recognizes other income when (or as) the Company satisfies each performance obligation.

Upon adoption of Topic 606, there was no change to the units of accounting previously identified with respect to existing service agreements under legacy Generally Accepted Accounting Principles (“GAAP”), which are now considered performance obligations under Topic 606, and there was no change to the revenue recognition pattern for the performance obligations. Accordingly, the adoption of the new standard resulted in no cumulative effect change to the Company's opening accumulated deficit balance.

The Company generally allocates the transaction price to distinct performance obligations at their stand-alone selling prices, determined by their estimated costs plus some margin. Performance obligations are generally delivered over time and recognized based upon observable inputs as the related research services are performed, which are recorded as research and development expenses. Amounts due under service agreements are generally billed monthly as services are delivered and do not generally result in contract liabilities or assets. Receivables under service agreements of $356,000 and $282,000 are included in prepaid expenses and other current assets as of September 30, 2019 and December 31, 2018, respectively. Contract liabilities of $92,000 and $200,000 are included in other current liabilities as of September 30, 2019 and December 31, 2018, respectively.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents include all cash balances and highly liquid investments purchased with an original maturity of three months or less.

The Company maintained restricted cash of $1,282,000 and $0 as of September 30, 2019 and December 31, 2018, respectively. This amount as of September 30, 2019 is included in deposits and other in the accompanying condensed consolidated balance sheets and is comprised solely of letters of credit required pursuant to leases for Company facilities.

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows.


	September 30,		December 31,
	2019		2018
Cash and cash equivalents	$	166,144	$	114,504
Restricted cash		1,282		—
Cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$	167,426	$	114,504

Investments

The Company considers securities purchased with original maturities greater than three months to be investments. The Company’s policy is to protect the value of its investment portfolio and minimize principal risk by earning returns based on current interest rates. The Company’s intent is to convert all investments into cash to be used for operations and has classified them as available for sale. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification. Interest and dividends on securities classified as available-for-sale are included in interest income.

Convertible Preferred Stock Warrants

The Company issued convertible preferred stock warrants, which were exercisable into Series A preferred stock with liquidation preference. The conversion feature was evaluated under ASC Topic 480 Distinguishing liabilities from equity and the warrants were determined to be debt instruments and classified prior to the IPO as liabilities on the consolidated balance sheets. The Company recorded these warrant liabilities at fair value and adjusted the carrying value to their estimated fair value at each reporting date with the increases or decreases in the fair value recorded as a gain (loss) on revaluation of the warrant liability in the consolidated statements of operations. Upon the IPO, the 49,997 preferred stock warrants were converted to common stock warrants of Class A shares and the warrant liability of $0.5 million was reclassified to additional paid-in capital as a result of the conversion. The warrants were not subject to further remeasurement for fair value.

Risks and Uncertainties

The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from similar services and larger companies, volatility of the industry, ability to obtain regulatory clearance, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company and general economic conditions.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents, investments and other receivables. Cash and cash equivalents are held at one financial institution and were in excess of the Federal Deposit Insurance Corporation insurable limit at September 30, 2019 and December 31, 2018. Additionally, cash and cash equivalents and investments are maintained at a brokerage firm for which amounts are insured by the Securities Investor Protection Corporation subject to legal limits. The Company has not experienced any losses on its deposits to date.

The Company does not require collateral or other security for other receivables; however, credit risk is mitigated by the Company’s ongoing evaluations of its debtors’ credit worthiness.

Research and Development Costs

Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits, consultant fees, stock-based compensation, certain facility costs, legal costs and other costs associated with preclinical development.

A substantial portion of the Company’s ongoing research and development activities are conducted by third-party service providers in connection with preclinical development activities and contract manufacturing organizations in connection with the production of materials for clinical trials. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs.

Stock‑Based Compensation

The Company generally grants stock options to its employees for a fixed number of shares with an exercise price equal to the fair value of the underlying shares at the date of grant. The Company accounts for stock option grants using the fair value method. The fair value of options is calculated using the Black‑Scholes option pricing model. Stock‑based compensation is recognized as the underlying options vest using the straight‑line attribution approach, and forfeitures are recorded as they occur.

Emerging Growth Company Status

The Company is an “emerging growth company,” (“EGC”) as defined in the Jumpstart Our Business Startups Act, (“JOBS Act”), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the Company’s condensed consolidated financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board (“FASB”) standards’ effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of the IPO or such earlier time that the Company is no longer an EGC.

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU 2016‑02 and subsequent amendments to the initial guidance under ASU 2017-13, ASU 2018-10, ASU 2018-11, and ASU 2019-01 (collectively, “Topic 842”), which modifies the accounting by lessees for all leases with a term greater than 12 months. This standard will require lessees to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. Topic 842 is effective for the Company as of January 1, 2021. Early adoption is permitted. The Company’s most significant lease is its operating lease for its corporate headquarters, and, while the Company has not yet estimated the amounts by which its financial statements will be affected by the adoption of this guidance, it expects that the overall recognition of expense will be similar to current guidance, but that there will be a significant change in the balance sheet due to the recognition of right of use assets and the corresponding lease liabilities.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (“Topic 326”): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04 and ASU 2019-05, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. The amendment replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. For available-for-sale debt securities, credit losses should be recorded through an allowance for credit losses. Topic 326 is effective for the Company as of January 1, 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.

In August 2016, the FASB issued ASU 2016‑15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (“Topic 230”). The standard clarifies how certain cash receipts and cash payments will be presented and classified in the statement of cash flows. Topic 230 is effective for the Company as of January 1, 2019. The adoption of this update had no material effect on the Company’s consolidated financial statements.

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2019

Fair Value of Financial Instruments

Fair Value of Financial Instruments

3. Fair Value of Financial Instruments

The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows:


	September 30, 2019
	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	59,820	$	—	$	—	$	59,820
U.S. Treasury securities		34,894		—		—		34,894
	$	94,714	$	—	$	—	$	94,714

	December 31, 2018
	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	109,630	$	—	$	—	$	109,630
Total	$	109,630	$	—	$	—	$	109,630
Liabilities
Warrant liability	$	—	$	—	$	380	$	380
Total	$	—	$	—	$	380	$	380

The Company utilized the market approach and Level 1 valuation inputs to value its money market funds and U.S. government treasury securities because published net asset values were readily available. As of September 30, 2019 and December 31, 2018, gross unrealized gains and unrealized losses for cash equivalents and short-term investments were not material, and the contractual maturity of all marketable securities was less than one year.

The fair value of the warrants was calculated using the Black-Scholes option pricing model and was revalued to fair value at the end of each reporting period until the warrants were converted to common stock warrants effective with the closing of the IPO on June 24, 2019. The liability was valued using the following assumptions:


	December 31,
	2018
Exercise price (1)	$	14.46
Stock price (2)	$	13.20
Time to maturity (in years)		3.64
Volatility (3)		83.7	%
Risk-free interest rate (4)		2.50	%
Expected dividend	$	—

(1)

Based upon terms provided in the warrant agreement.

(2)

Based upon an independently prepared valuation as of December 31, 2018, adjusted for the one-for-six reverse stock split.

(3)

Based upon the historical daily volatility of a group of peer public company closing prices.

(4)

Based upon interest rate for U.S. Treasury Bonds, as published by the U.S. Federal Reserve.

The preferred stock warrants were previously valued at Level 3 as there were no observable inputs supported by market activity. The Company estimated the fair value of the preferred stock warrants using the Black-Scholes model which considers various potential liquidity outcomes and assigned probabilities to each to arrive at the weighted equity value. Upon the IPO, the 49,997 preferred stock warrants were revalued and converted to common stock warrants of Class A shares and the warrant liability of $0.5 million was reclassified to additional paid-in capital as a result of the conversion. Revaluation upon IPO was performed using the following assumptions: expected life of 3.17 years; fair value of Series A of $17.00 per share; risk-free interest rate of 1.69%; volatility of 83.61% and no expected dividends. For further information regarding convertible preferred stock warrants, refer to Note 9, Capital Stock.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Cash, Cash Equivalents and Investments

9 Months Ended

Sep. 30, 2019

Cash, Cash Equivalents and Investments

Cash, Cash Equivalents and Investments

4. Cash, Cash Equivalents and Investments

The fair value and the amortized cost of cash, cash equivalents and available-for-sale investments by major security type consist of the following (in thousands):


	As of September 30, 2019
			Gross		Gross		Estimated
	Amortized		Unrealized		Unrealized		Fair
Cash and cash equivalents and investments	Cost		Gains		Losses		Value
Cash and money market funds	$	166,144	$	—	$	—	$	166,144
U.S. Treasury securities		34,846		48		—		34,894
Total		200,990		48		—		201,038
Less amounts classified as cash and cash equivalents		(166,144)		—		—		(166,144)
Total available-for-sale investments	$	34,846	$	48	$	—	$	34,894


	As of December 31, 2018
			Gross		Gross		Estimated
	Amortized		Unrealized		Unrealized		Fair
Cash and cash equivalents and investments	Cost		Gains		Losses		Value
Cash and money market funds	$	114,504	$	—	$	—	$	114,504
Total		114,504		—		—		114,504
Less amounts classified as cash and cash equivalents		(114,504)		—		—		(114,504)
Total available-for-sale investments	$	—	$	—	$	—	$	—

Prepaid Expenses and Other Current Assets

9 Months Ended

Sep. 30, 2019

Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

5. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	September 30,		December 31,
	2019		2018
Prepaid insurance	$	1,922	$	36
Prepaid rent		1,882		394
Vendor prepayments and deposits		1,095		2,009
Non-trade receivables		357		282
Interest receivables and other current assets		178		—
Total prepaid expenses and other current assets	$	5,434	$	2,721

Property and Equipment, net

9 Months Ended

Sep. 30, 2019

Property and Equipment, net

Property and Equipment, net

6. Property and Equipment, net

Property and equipment consists of the following (in thousands):


	September 30,		December 31,
	2019		2018
Laboratory equipment	$	9,132	$	7,561
Furniture and fixtures		389		386
Computer hardware and software		732		580
Leasehold improvements		247		236
		10,500		8,763
Less accumulated depreciation and amortization		(5,760)		(4,620)
Total property and equipment, net	$	4,740	$	4,143

Depreciation expense was $426,000 and $360,000 for the three months ended September 30, 2019 and 2018, respectively, and $1,218,000 and $1,027,000 for the nine months ended September 30, 2019 and 2018, respectively.

The net book value of property and equipment under capital leases was $105,000 and $142,000 at September 30, 2019 and December 31, 2018, respectively.

Accrued Expenses

9 Months Ended

Sep. 30, 2019

Accrued Expenses

Accrued Expenses

7. Accrued Expenses

Accrued expenses consist of the following (in thousands):


	September 30,		December 31,
	2019		2018
Compensation and related benefits	$	2,726	$	2,568
Professional fees		496		183
Contract research fees		690		43
Other		607		214
Total accrued expenses	$	4,519	$	3,008

Commitments and Contingencies

9 Months Ended

Sep. 30, 2019

Commitments and Contingencies

Commitments and Contingencies

8. Commitments and Contingencies

Leases

The Company leases its office facilities under non-cancellable operating lease agreements that expire at various dates through May 2033. Under the terms of the leases, the Company is responsible for certain insurance, property taxes and maintenance expenses. The office facilities lease agreements contain scheduled increases over the lease term. The related rent expense is calculated on a straight-line basis with the difference recorded as deferred rent. Rent expense was $1,092,000 and $313,000 for the three months ended September 30, 2019 and 2018, respectively, and $2,352,000 and $938,000 for the nine months ended September 30, 2019 and 2018, respectively.

The Company leases certain property and equipment under capital leases. In 2017, the Company financed purchases of $226,000 under a capital lease agreement. Outstanding amounts under the capital lease agreements are generally secured by liens on the related property and equipment.

Future minimum lease payments under non-cancelable operating and capital lease agreements consisted of the following at September 30, 2019 (in thousands):


	Capital		Operating
	Leases		Leases
Years ending December 31:
2019 (remaining 3 months)	$	12	$	1,717
2020		51		5,734
2021		51		5,716
2022		4		7,311
2023		—		7,012
Thereafter		—		77,226
Total minimum lease payments		118	$	104,716
Less: amount representing interest		(7)
Present value of capital lease obligation		111
Less: current portion		(46)
Non-current portion	$	65

Litigation

The Company is not aware of any asserted or unasserted claims against it where it believes that an unfavorable resolution would have an adverse material impact on the operations or financial position of the Company.

Capital Stock	9 Months Ended
Capital Stock	Sep. 30, 2019
Capital Stock
Capital Stock	9. Capital Stock Class A and Class B Common Stock On June 2, 2019 the board of directors of the Company authorized the issuance of 650,000,000 shares of Class A common stock, $0.0001 par value per share, 50,000,000 shares of Class B common stock, $0.0001 par value per share and 300,000,000 shares of preferred stock, $0.0001 par value per share, upon the filing of the Company’s Amended and Restated Certificate of Incorporation in connection with the reverse stock split. Each holder of Class A common stock will be entitled to one vote and each holder of Class B common stock is not entitled to vote except as may be required by law and shall not be entitled to vote on the election of directors at any time. Convertible Preferred Stock Warrant Upon the IPO, the 49,997 preferred stock warrants were revalued and converted to common stock warrants of Class A common stock shares and the warrant liability of $0.5 million was reclassified to additional paid-in capital as a result of the conversion. The warrants were not subject to further remeasurement for fair value. The balances of the preferred stock warrant liabilities were zero and $0.4 million, respectively, as of September 30, 2019 and December 31, 2018. Common Stock Warrant In connection with the issuance of Series A in August 2015, the Company issued a warrant to purchase an aggregate of 62,936 shares of common stock at $0.0001 per share. The warrant was immediately exercisable and expires, if not exercised, in August 2025. At issuance, the fair value of the warrant was determined to be $41,509, which was recorded as a Series A preferred stock issuance cost and additional paid-in capital. The warrant was exercised in full during the three months ended September 30, 2019 and the Company issued 62,936 shares of Class A common stock upon such exercise.

Equity Incentive Plan

9 Months Ended

Sep. 30, 2019

Stock Option Plan

Stock Option Plan

10. Equity Incentive Plans

2019 Equity Incentive Plan

The Company’s board of directors adopted and our stockholders approved our 2019 Equity Incentive Plan, (the “2019 Plan”), on June 2, 2019, and June 7, 2019, respectively. The 2019 Plan became effective on June 19, 2019, and no further grants will be made under the Company’s 2010 Equity Incentive Plan. The purpose of the 2019 Plan, through the grant of stock awards including stock options and other stock-based awards, including restricted stock units (“RSUs”), is to help us secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for our success and that of our affiliates, and provide a means by which the eligible recipients may benefit from increases in the value of our Class A common stock. Under the 2019 Plan, 6,141,842 shares of the Company’s Class A common stock have been reserved for issuance to employees, directors and consultants. Additionally, the number of shares of our Class A common stock reserved for issuance under our 2019 Plan will automatically increase on January 1 of each year, beginning on January 1, 2020 and continuing through and including January 1, 2029, by 4% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our board of directors.

Stock option activity under the Plan is as follow:


	Options Outstanding
				Weighted-
				Average	Aggregate
		Weighted-		Remaining	Intrinsic
	Number	Average		Contractual	Value
	of Shares	Exercise Price		Life (years)	(in thousands)
Balances, December 31, 2018	2,136,291	$	6.06	8.9	$	12,881
Granted	1,658,012		13.68
Exercised	(67,243)		3.83
Cancelled	(36,662)		11.03
Balances, September 30, 2019	3,690,398	$	9.46	8.8	$	12,830
Vested and expected to vest at September 30, 2019	3,690,398	$	9.46	8.8	$	12,830
Exercisable at September 30, 2019	1,736,235	$	5.56	8.1	$	11,606
Vested at September 30, 2019	993,078	$	5.91	7.8	$	6,296

The weighted‑average grant date fair value of options granted to employees and non‑employees in the nine months ended September 30, 2019 and 2018 was $10.42 and $3.57, respectively. The fair value of each option is estimated on the date of grant using the Black‑Scholes option pricing model, assuming no expected dividends and the following weighted average assumptions:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Expected life (in years)	6.03		*		6.02		6.01
Volatility	80.5	%	*	%	80.8	%	78.3	%
Risk-free interest rate	1.77	%	*	%	2.19	%	2.88	%

* No stock options granted during the three months ended September 30, 2018

Expected volatility is based on volatilities of public companies operating in the Company’s industry. The expected life of the options is estimated using the simplified method detailed in SEC Staff Accounting Bulletin No. 107. The simplified method calculates the expected term as the mid-point between the weighted-average time to vesting and the contractual maturity. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company has elected to account for forfeitures as they occur, rather than estimate expected forfeitures.

2019 Employee Stock Purchase Plan

The Company’s board of directors adopted the 2019 Employee Stock Purchase Plan, (“ESPP”), on June 2, 2019, and the Company’s stockholders approved the ESPP on June 7, 2019. The ESPP became effective on June 19, 2019. The Company’s board of directors authorized 283,333 shares of Class A common stock to be reserved for future issuance under the ESPP. The number of shares of our Class A common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2020 through January 1, 2029, by the lesser of (1) 1% of the total number of shares of our Class A common stock outstanding on December 31 of the preceding calendar year, and (2) 416,666 shares; provided, that prior to the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (1) and (2). During the three months and nine months ended September 30, 2019, the expense related to the ESPP was $177,000. The fair value of each ESPP is estimated on the date of grant using the Black‑Scholes option pricing model, assuming no expected dividends and the following range of assumptions:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Expected life (in years)	0.2-2.0		—		0.2-2.0		—
Volatility	74.5-101.6	%	—	%	74.5-101.6	%	—	%
Risk-free interest rate	1.50- 2.15	%	—	%	1.50-2.15	%	—	%

The Company recognized $1,878,000 and $342,000 of stock‑based compensation expense related to options and ESPP granted to employees and non‑employees for the three months ended September 30, 2019 and 2018, respectively. The Company recognized $4,013,000 and $832,000 of stock‑based compensation expense related to options and ESPP granted to employees and non‑employees for the nine months ended September 30, 2019 and 2018, respectively. The compensation expense is allocated on a departmental basis, based on the classification of the option holder as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and development	$	920	$	147	$	2,091	$	357
General and administrative		958		195		1,922		475
	$	1,878	$	342	$	4,013	$	832

No income tax benefits have been recognized in the statements of operations for stock‑based compensation arrangements and no stock‑based compensation costs have been capitalized as property and equipment as of September 30, 2019.

Unrecognized estimated compensation expense as of September 30, 2019 totaled $20.9 million related to non‑vested stock options with a remaining requisite service period of 3.3 years.

Net Loss Per Share

9 Months Ended

Sep. 30, 2019

401(k) Plan

Net Loss Per Share

12. Net Loss Per Share

The following outstanding potentially dilutive common shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because the impact of including them would have been antidilutive:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Convertible preferred stock (as converted)		—		17,248,259		—		17,248,259
Common stock options		3,690,398		1,638,380		3,690,398		1,638,380
Common stock warrants		49,997		62,936		49,997		62,936
Convertible preferred stock warrants		—		49,997		—		49,997
Early exercised stock options		2,284		—		2,284		—
		3,742,679		18,999,572		3,742,679		18,999,572

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2019
Related Party Transactions
Related Party Transactions	13. Related Party Transactions The Company recorded other income of $3,000 and $100,000 for the three months ended September 30, 2019 and 2018, respectively, and $486,000 and $595,000 for the nine months ended September 30, 2019 and 2018, respectively, under service contracts with a stockholder. The Company had a receivable from the stockholder at September 30, 2019 and December 31, 2018 of $1,000 and $89,000, respectively. The Company recorded expense of $402,000 and $230,000 during the three months ended September 30, 2019 and 2018, respectively, and $1.1 million and $844,000 during the nine months ended September 30, 2019 and 2018, respectively, related to intellectual property and other legal services performed by a related party. The Company owed $358,000 and $104,000 to the related party at September 30, 2019 and December 31, 2018, respectively. The Company recorded expense of $309,000 and $205,000 during the three months ended September 30, 2019 and 2018, respectively, and $2.3 million and $417,000 during the nine months ended September 30, 2019 and 2018, respectively, related to legal services performed by a related party. The Company owed $302,000 and $130,000 to the related party at September 30, 2019 and December 31, 2018, respectively. The Company recorded research and development expense of $123,000 and $100,000 during three months ended September 30, 2019 and 2018, respectively, and $335,000 and $300,000 during nine months ended September 30, 2019 and 2018, respectively, under consulting agreements with two members of the Company’s board of directors. The Company owed $20,000 and zero to the members of the Company’s board of directors at September 30, 2019 and December 31, 2018, respectively.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2019

Summary of Significant Accounting Policies

Principles of Consolidation

Basis of Presentation

Prior period reclassification

An immaterial reclassification of prior period amounts has been made to conform to the current period presentation.

Principles of Consolidation

Use of Estimates

Unaudited Interim Condensed Financial Statements

Unaudited Interim Condensed Consolidated Financial Statements

Other Income

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents include all cash balances and highly liquid investments purchased with an original maturity of three months or less.


	September 30,		December 31,
	2019		2018
Cash and cash equivalents	$	166,144	$	114,504
Restricted cash		1,282		—
Cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$	167,426	$	114,504

Investments

Convertible Preferred Stock Warrants

Risks and Uncertainties

Concentration of Credit Risk

The Company does not require collateral or other security for other receivables; however, credit risk is mitigated by the Company’s ongoing evaluations of its debtors’ credit worthiness.

Research and Development Costs

Preferred Stock Warrant Liability

Stock‑Based Compensation

Emerging Growth Company Status

Net Loss Per Share


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Convertible preferred stock (as converted)		—		17,248,259		—		17,248,259
Common stock options		3,690,398		1,638,380		3,690,398		1,638,380
Common stock warrants		49,997		62,936		49,997		62,936
Convertible preferred stock warrants		—		49,997		—		49,997
Early exercised stock options		2,284		—		2,284		—
		3,742,679		18,999,572		3,742,679		18,999,572

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2019

Summary of Significant Accounting Policies

Schedule of reconciliation of cash and cash equivalents and restricted cash


	September 30,		December 31,
	2019		2018
Cash and cash equivalents	$	166,144	$	114,504
Restricted cash		1,282		—
Cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$	167,426	$	114,504

Summary of unaudited pro forma net loss per share


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Convertible preferred stock (as converted)		—		17,248,259		—		17,248,259
Common stock options		3,690,398		1,638,380		3,690,398		1,638,380
Common stock warrants		49,997		62,936		49,997		62,936
Convertible preferred stock warrants		—		49,997		—		49,997
Early exercised stock options		2,284		—		2,284		—
		3,742,679		18,999,572		3,742,679		18,999,572

Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2019

Fair Value of Financial Instruments

Summary of financial assets and liabilities subject to fair value measurements on a recurring basis


	September 30, 2019
	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	59,820	$	—	$	—	$	59,820
U.S. Treasury securities		34,894		—		—		34,894
	$	94,714	$	—	$	—	$	94,714

	December 31, 2018
	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	109,630	$	—	$	—	$	109,630
Total	$	109,630	$	—	$	—	$	109,630
Liabilities
Warrant liability	$	—	$	—	$	380	$	380
Total	$	—	$	—	$	380	$	380

Summary of fair value of the warrants were calculated using the Black-Scholes option pricing model


	December 31,
	2018
Exercise price (1)	$	14.46
Stock price (2)	$	13.20
Time to maturity (in years)		3.64
Volatility (3)		83.7	%
Risk-free interest rate (4)		2.50	%
Expected dividend	$	—

(1)

Based upon terms provided in the warrant agreement.

(2)

Based upon an independently prepared valuation as of December 31, 2018, adjusted for the one-for-six reverse stock split.

(3)

Based upon the historical daily volatility of a group of peer public company closing prices.

Based upon interest rate for U.S. Treasury Bonds, as published by the U.S. Federal Reserve.

Cash, Cash Equivalents and Investments (Tables)

9 Months Ended

Sep. 30, 2019

Cash, Cash Equivalents and Investments

Summary of fair value and the amortized cost of cash, cash equivalents and available-for-sale investments by major security type


	As of September 30, 2019
			Gross		Gross		Estimated
	Amortized		Unrealized		Unrealized		Fair
Cash and cash equivalents and investments	Cost		Gains		Losses		Value
Cash and money market funds	$	166,144	$	—	$	—	$	166,144
U.S. Treasury securities		34,846		48		—		34,894
Total		200,990		48		—		201,038
Less amounts classified as cash and cash equivalents		(166,144)		—		—		(166,144)
Total available-for-sale investments	$	34,846	$	48	$	—	$	34,894


	As of December 31, 2018
			Gross		Gross		Estimated
	Amortized		Unrealized		Unrealized		Fair
Cash and cash equivalents and investments	Cost		Gains		Losses		Value
Cash and money market funds	$	114,504	$	—	$	—	$	114,504
Total		114,504		—		—		114,504
Less amounts classified as cash and cash equivalents		(114,504)		—		—		(114,504)
Total available-for-sale investments	$	—	$	—	$	—	$	—

Prepaid Expenses and Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2019

Prepaid Expenses and Other Current Assets

Summary of Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following (in thousands):


	September 30,		December 31,
	2019		2018
Prepaid insurance	$	1,922	$	36
Prepaid rent		1,882		394
Vendor prepayments and deposits		1,095		2,009
Non-trade receivables		357		282
Interest receivables and other current assets		178		—
Total prepaid expenses and other current assets	$	5,434	$	2,721

Property and Equipment, net (Tables)

9 Months Ended

Sep. 30, 2019

Property and Equipment, net

Summary of property and equipment

Property and equipment consists of the following (in thousands):


	September 30,		December 31,
	2019		2018
Laboratory equipment	$	9,132	$	7,561
Furniture and fixtures		389		386
Computer hardware and software		732		580
Leasehold improvements		247		236
		10,500		8,763
Less accumulated depreciation and amortization		(5,760)		(4,620)
Total property and equipment, net	$	4,740	$	4,143

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2019

Accrued Expenses

Summary of accrued expenses

Accrued expenses consist of the following (in thousands):


	September 30,		December 31,
	2019		2018
Compensation and related benefits	$	2,726	$	2,568
Professional fees		496		183
Contract research fees		690		43
Other		607		214
Total accrued expenses	$	4,519	$	3,008

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2019

Commitments and Contingencies

Schedule of future minimum lease payments under non-cancelable operating and capital lease agreements

Future minimum lease payments under non-cancelable operating and capital lease agreements consisted of the following at September 30, 2019 (in thousands):


	Capital		Operating
	Leases		Leases
Years ending December 31:
2019 (remaining 3 months)	$	12	$	1,717
2020		51		5,734
2021		51		5,716
2022		4		7,311
2023		—		7,012
Thereafter		—		77,226
Total minimum lease payments		118	$	104,716
Less: amount representing interest		(7)
Present value of capital lease obligation		111
Less: current portion		(46)
Non-current portion	$	65

Equity Incentive Plan (Tables)

9 Months Ended

Sep. 30, 2019

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of stock option activity


	Options Outstanding
				Weighted-
				Average	Aggregate
		Weighted-		Remaining	Intrinsic
	Number	Average		Contractual	Value
	of Shares	Exercise Price		Life (years)	(in thousands)
Balances, December 31, 2018	2,136,291	$	6.06	8.9	$	12,881
Granted	1,658,012		13.68
Exercised	(67,243)		3.83
Cancelled	(36,662)		11.03
Balances, September 30, 2019	3,690,398	$	9.46	8.8	$	12,830
Vested and expected to vest at September 30, 2019	3,690,398	$	9.46	8.8	$	12,830
Exercisable at September 30, 2019	1,736,235	$	5.56	8.1	$	11,606
Vested at September 30, 2019	993,078	$	5.91	7.8	$	6,296

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Expected life (in years)	6.03		*		6.02		6.01
Volatility	80.5	%	*	%	80.8	%	78.3	%
Risk-free interest rate	1.77	%	*	%	2.19	%	2.88	%

Schedule of stock-based compensation expense

The compensation expense is allocated on a departmental basis, based on the classification of the option holder as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and development	$	920	$	147	$	2,091	$	357
General and administrative		958		195		1,922		475
	$	1,878	$	342	$	4,013	$	832

2019 Employee Stock Purchase Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Expected life (in years)	0.2-2.0		—		0.2-2.0		—
Volatility	74.5-101.6	%	—	%	74.5-101.6	%	—	%
Risk-free interest rate	1.50- 2.15	%	—	%	1.50-2.15	%	—	%

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2019

401(k) Plan

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Convertible preferred stock (as converted)		—		17,248,259		—		17,248,259
Common stock options		3,690,398		1,638,380		3,690,398		1,638,380
Common stock warrants		49,997		62,936		49,997		62,936
Convertible preferred stock warrants		—		49,997		—		49,997
Early exercised stock options		2,284		—		2,284		—
		3,742,679		18,999,572		3,742,679		18,999,572

Business (Details) $ / shares in Units, $ in Thousands		1 Months Ended	9 Months Ended	12 Months Ended
Business (Details) $ / shares in Units, $ in Thousands	Jun. 07, 2019	Jun. 30, 2019 USD ($) $ / shares shares	Sep. 30, 2019 USD ($) shares	Dec. 31, 2018
Business
Reverse stock split	0.167			0.167
Proceeds from Issuance Initial Public Offering \| $			$ 133,633
underwriting discounts and commissions \| $		$ 10,100
Offering expenses \| $		2,800
Warrants to purchase (in shares) \| shares			49,997
Conversion of redeemable convertible preferred stock to common stock \| $		209,700	$ 209,669
Deferred offering cost \| $		$ 2,800
Payment of deferred offering cost \| $			$ 2,848
IPO
Business
Offering price \| $ / shares		$ 17.00
Proceeds from Issuance Initial Public Offering \| $		$ 130,800
Class A common stock
Business
Number of shares issued up on conversion \| shares		13,314,068
Warrants to purchase (in shares) \| shares		62,936
Class A common stock \| IPO
Business
Shares issued \| shares		6,452,500
Class A common stock \| underwriters option
Business
Shares issued \| shares		1,102,500
Class B common stock
Business
Number of shares issued up on conversion \| shares		3,934,191
Class B common stock \| IPO
Business
Shares issued \| shares		2,000,000

Summary of Significant Accounting Policies (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Cash and cash equivalents and restricted cash reported within the condensed balance sheets
Cash and cash equivalents	$ 166,144,000	$ 114,504,000
Restricted cash	1,282,000	0
Cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$ 167,426,000	114,504,000	$ 125,886,000	$ 8,242,000
Convertible Preferred Stock Warrants
Warrants to purchase (in shares)	49,997
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital	$ 503,000
Prepaid expenses and other current assets
Other Income
Receivables under service agreements	356,000	282,000
Other current liabilities
Other Income
Contract liabilities	$ 92,000	$ 200,000

Fair Value of Financial Instruments - Financial assets and liabilities (Details) - Recurring basis - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Assets
Total assets	$ 94,714	$ 109,630
Liabilities
Total liabilities		380
Common stock warrants
Liabilities
Total liabilities		380
Cash and money market funds
Assets
Total assets	59,820	109,630
U.S. Treasury securities
Assets
Total assets	34,894
Level 1
Assets
Total assets	94,714	109,630
Level 1 \| Cash and money market funds
Assets
Total assets	59,820	109,630
Level 1 \| U.S. Treasury securities
Assets
Total assets	$ 34,894
Level 3
Liabilities
Total liabilities		380
Level 3 \| Common stock warrants
Liabilities
Total liabilities		$ 380

Fair Value of Financial Instruments - Fair value of the warrants (Details) $ in Thousands		9 Months Ended	12 Months Ended
	Jun. 07, 2019	Sep. 30, 2019 USD ($) item shares	Dec. 31, 2018 item
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Reverse stock split	0.167		0.167
Warrant liability, measurement input		17.00
Warrants to purchase (in shares) \| shares		49,997
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital \| $		$ 503
Expected life		3 years 2 months 1 day	3 years 7 months 21 days
Exercise price (1)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input			14.46
Stock price (2)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input			13.20
Volatility (3)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input		0.8361	0.837
Risk-free interest rate (4)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input		0.0169	0.0250
Expected dividend
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input		0.00

Cash, Cash Equivalents and Investments - Fair value and Amortized cost (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Cash and money market funds
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Amortized Cost	$ 166,144	$ 114,504
Estimated Fair Value	166,144	114,504
U.S. Treasury securities
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Amortized Cost	34,846
Gross Unrealized Gains	48
Estimated Fair Value	34,894
Total
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Amortized Cost	200,990	114,504
Gross Unrealized Gains	48
Estimated Fair Value	201,038	114,504
Less amounts classified as cash and cash equivalents
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Amortized Cost	166,144	114,504
Estimated Fair Value	166,144	$ 114,504
Total available-for-sale investments
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Amortized Cost	34,846
Gross Unrealized Gains	48
Estimated Fair Value	$ 34,894

Prepaid Expenses and Other Current Assets - Prepaid expenses and other current assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Prepaid Expenses and Other Current Assets
Prepaid Insurance	$ 1,922	$ 36
Prepaid rent	1,882	394
Vendor prepayments and deposits	1,095	2,009
Non-trade receivables	357	282
Interest receivables and other current assets	178
Total prepaid expenses and other current assets	$ 5,434	$ 2,721

Property and Equipment, net (Details) - USD ($)	3 Months Ended		9 Months Ended
Property and Equipment, net (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Property, Plant and Equipment, Net, by Type [Abstract]
Property, Plant and Equipment, Gross	$ 10,500,000		$ 10,500,000		$ 8,763,000
Less accumulated depreciation and amortization	(5,760,000)		(5,760,000)		(4,620,000)
Total property and equipment, net	4,740,000		4,740,000		4,143,000
Depreciation expense	426,000	$ 360,000	1,218,000	$ 1,027,000
Net book value of property and equipment under capital leases	105,000		105,000		142,000
Laboratory equipment
Property, Plant and Equipment, Net, by Type [Abstract]
Property, Plant and Equipment, Gross	9,132,000		9,132,000		7,561,000
Furniture and fixtures
Property, Plant and Equipment, Net, by Type [Abstract]
Property, Plant and Equipment, Gross	389,000		389,000		386,000
Computer hardware and software
Property, Plant and Equipment, Net, by Type [Abstract]
Property, Plant and Equipment, Gross	732,000		732,000		580,000
Leasehold improvements
Property, Plant and Equipment, Net, by Type [Abstract]
Property, Plant and Equipment, Gross	$ 247,000		$ 247,000		$ 236,000

Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued Expenses
Compensation and related benefits	$ 2,726	$ 2,568
Professional fees	496	183
Contract research fees	690	43
Other	607	214
Total accrued expenses	$ 4,519	$ 3,008

Commitments and Contingencies - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Future minimum capital leases:
2019 (remaining 3 months)	$ 12
2020	51
2021	51
2022	4
Total minimum lease payments	118
Less: amount representing interest	(7)
Present value of capital lease obligation	111
Less: current portion	46
Non-current portion	65	$ 100
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2019 (remaining 3 months)	1,717
2020	5,734
2021	5,716
2022	7,311
2023	7,012
Thereafter	77,226
Total minimum lease payments	$ 104,716

Capital Stock - Class A and Class B Common Stock (Details)	Jun. 02, 2019 Vote $ / shares shares	Sep. 30, 2019 $ / shares shares	Dec. 31, 2018 $ / shares shares
Class of Stock [Line Items]
Preferred Stock, Shares Authorized \| shares	300,000,000
Preferred stock par value \| $ / shares	$ 0.0001
Class A common stock
Class of Stock [Line Items]
Common stock, shares authorized \| shares	650,000,000	650,000,000	191,398,492
Common stock, par value \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Number of votes entitled per share \| Vote	1
Class B common stock
Class of Stock [Line Items]
Common stock, shares authorized \| shares	50,000,000	50,000,000	23,605,150
Common stock, par value \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001

Capital Stock - Convertible Preferred Stock Warrant (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Class of Warrant or Right [Line Items]
Warrants to purchase (in shares)	49,997
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital	$ 503
Preferred stock warrant liability		$ 380
Preferred Stock Warrants
Class of Warrant or Right [Line Items]
Warrants to purchase (in shares)	49,997
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital	$ 500
Preferred stock warrant liability	$ 0	$ 400

Capital Stock - Common Stock Warrants (Details) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 31, 2015	Sep. 30, 2019	Jun. 30, 2019
Class of Warrant or Right [Line Items]
Warrants to purchase (in shares)		49,997
Class A common stock
Class of Warrant or Right [Line Items]
Warrants to purchase (in shares)			62,936
Common Stock Warrants \| Class A common stock
Class of Warrant or Right [Line Items]
Exercise of warrants		62,936
Common Stock Warrants \| Series A convertible preferred stock
Class of Warrant or Right [Line Items]
Warrants to purchase (in shares)	62,936
Price per share (in dollars per share)	$ 0.0001
Fair value of warrants	$ 41,509

Equity Incentive Plan - Narrative (Details) - 2019 Equity Incentive Plan	Jun. 19, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	6,141,842
Percentage of additional number of shares authorized annually	4.00%

Equity Incentive Plan - Stock option (Details) - 2019 Equity Incentive Plan	9 Months Ended	12 Months Ended
	Sep. 30, 2019 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares
Number of Shares
Balance at beginning of period (in shares) \| shares	2,136,291
Granted (in shares) \| shares	1,658,012
Exercised (in shares) \| shares	(67,243)
Cancelled (in shares) \| shares	(36,662)
Balance at end of period (in shares) \| shares	3,690,398	2,136,291
Vested and expected to vest at end of period (in shares) \| shares	3,690,398
Exercisable at end of period (in shares) \| shares	1,736,235
Vested at end of period (in shares) \| shares	993,078
Weighted-Average Exercise Price
Balance at beginning of period (in dollars per share) \| $ / shares	$ 6.06
Granted (in dollars per share) \| $ / shares	13.68
Exercised (in dollars per share) \| $ / shares	3.83
Cancelled (in dollars per share) \| $ / shares	11.03
Balance at end of period (in dollars per share) \| $ / shares	9.46	$ 6.06
Vested and expected to vest at end of period (in dollars per share) \| $ / shares	9.46
Exercisable at end of period (in dollars per share) \| $ / shares	5.56
Vested at end of period (in dollars per share) \| $ / shares	$ 5.91
Weighted-Average Remaining Contractual Life
Weighted-Average Remaining Contractual Life	8 years 9 months 18 days	8 years 10 months 24 days
Vested and expected to vest at end of period (in years)	8 years 9 months 18 days
Exercisable at end of period (in years)	8 years 1 month 6 days
Vested at end of period (in years)	7 years 9 months 18 days
Aggregate Intrinsic Value
Balance at end of period \| $	$ 12,830	$ 12,881
Vested and expected to vest at end of period \| $	12,830
Exercisable at end of period \| $	11,606
Vested at end of period \| $	$ 6,296

Equity Incentive Plan - Weighted-average grant date fair value (Details) - 2019 Equity Incentive Plan - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)	$ 10.42	$ 3.57
Expected dividend	0.00%	0.00%

Equity Incentive Plan - Weighted average assumptions (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life (in years)	6 years 11 days
Volatility	80.50%
Risk-free interest rate	1.77%
2019 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life (in years)		6 years 7 days	6 years 4 days
Volatility		80.80%	78.30%
Risk-free interest rate		2.19%	2.88%
2019 Employee Stock Purchase Plan \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life (in years)	2 months 12 days	2 months 12 days
Volatility	74.50%	74.50%
Risk-free interest rate	1.50%	1.50%
2019 Employee Stock Purchase Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life (in years)	2 years	2 years
Volatility	101.60%	101.60%
Risk-free interest rate	2.15%	2.15%

Equity Incentive Plan - 2019 Employee Stock Purchase Plan (Details) - USD ($)		3 Months Ended		9 Months Ended
	Jun. 19, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 1,878,000	$ 342,000	$ 4,013,000	$ 832,000
Class A common stock \| 2019 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	283,333
Stock-based compensation expense		$ 177,000		$ 177,000
Expected dividend				0.00%
Class A common stock \| 2019 Employee Stock Purchase Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of additional number of shares authorized annually	1.00%
Additional number of shares authorized annually	416,666

Equity Incentive Plan - Stock-based compensation expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 1,878,000	$ 342,000	$ 4,013,000	$ 832,000
Income tax benefits for stock-based compensation			0
Stock-based compensation costs capitalized			0
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	920,000	147,000	2,091,000	357,000
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 958,000	$ 195,000	$ 1,922,000	$ 475,000

Equity Incentive Plan - Unrecognized compensation (Details) - 2019 Equity Incentive Plan $ in Millions	9 Months Ended
	Sep. 30, 2019 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized estimated compensation expense	$ 20.9
Remaining requisite service period	3 years 3 months 18 days

Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
Net Loss Per Share (Details) - shares	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in the diluted net loss per share calculation	3,742,679	18,999,572	3,742,679	18,999,572
Convertible preferred stock (as converted)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in the diluted net loss per share calculation		17,248,259		17,248,259
Common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in the diluted net loss per share calculation	3,690,398	1,638,380	3,690,398	1,638,380
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in the diluted net loss per share calculation	49,997	62,936	49,997	62,936
Convertible preferred stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in the diluted net loss per share calculation		49,997		49,997
Early exercised stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in the diluted net loss per share calculation	2,284		2,284

Related Party Transactions (Details)	3 Months Ended		9 Months Ended
Related Party Transactions (Details)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) director	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Related Party Transaction [Line Items]
Other income	$ 3,000	$ 100,000	$ 486,000	$ 595,000
Receivable from stockholders	1,000		1,000		$ 89,000
Due to related party	20,000		20,000		0
Research and development expense	123,000	100,000	$ 335,000	300,000
Number of members under consulting agreements \| director			2
Intellectual property related legal fees
Related Party Transaction [Line Items]
Legal fees	402,000	230,000	$ 1,100,000	844,000
Due to related party	358,000		358,000		104,000
Other legal fees
Related Party Transaction [Line Items]
Legal fees	309,000	$ 205,000	2,300,000	$ 417,000
Due to related party	$ 302,000		$ 302,000		$ 130,000

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2019
Subsequent Events
Subsequent Events	14. Subsequent Events The Company has evaluated subsequent events that may require adjustments to or disclosure in the unaudited interim condensed consolidated financial statements through November 12, 2019, the date on which the unaudited interim condensed consolidated financial statements were available to be issued.

Commitments and Contingencies (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2017
Operating leases
Rent expenses	$ 1,092,000	$ 313,000	$ 2,352,000	$ 938,000
Capital lease
Purchases under capital lease					$ 226,000